CAY10594

CAT: 0804-HY-121983-01Size: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-121983-01Size:1 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
CAY10594 is an orally active PLD2 inhibitor with an IC50 of 140 nM. CAY10594 has activities such as anti-tumor, anti-oxidation and liver protection. CAY10594 can be used for the research of diseases like breast cancer, acute liver injury and colitis[1][2][3][4].
CAS Number
[1130067-34-3]
UNSPSC
12352005
Target
Anaplastic lymphoma kinase (ALK) ; Apoptosis; CXCR; G Protein-coupled Receptor Kinase (GRK) ; GSK-3; Interleukin Related; Lactate Dehydrogenase; Phospholipase; STAT
Type
Reference compound
Related Pathways
Apoptosis; GPCR/G Protein; Immunology/Inflammation; JAK/STAT Signaling; Metabolic Enzyme/Protease; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
Cancer-programmed cell death
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/cay10594.html
Purity
98.64
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C(C1=CC2=C(C=C1)C=CC=C2)NCCN3CCC4(CC3)C(NCN4C5=CC=CC=C5)=O
Molecular Formula
C26H28N4O2
Molecular Weight
428.53
References & Citations
[1]Scott SA, et al. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol. 2009 Feb;5 (2) :108-17.|[2]Lee SK, et al. A phospholipase D2 inhibitor, CAY10594, ameliorates acetaminophen-induced acute liver injury by regulating the phosphorylated-GSK-3β/JNK axis. Sci Rep. 2019 May 10;9 (1) :7242. |[3]Qian T, et al. PLD2 deletion alleviates disruption of tight junctions in sepsis-induced ALI by regulating PA/STAT3 phosphorylation pathway. Int Immunopharmacol. 2023 Jan;114:109561.|[4]Zhou G, et al. Blockade of PLD2 Ameliorates Intestinal Mucosal Inflammation of Inflammatory Bowel Disease. Mediators Inflamm. 2016;2016:2543070.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CXCR2; GRK2; GSK-3β; IL-1; IL-17; IL-23; IL-6; STAT3

Related Products

CatalogName
HY-118514CAY10514
HY-120441CAY10590
HY-118180CAY10595
HY-117008-01CAY10589
HY-118119-01CAY10526
HY-138985-01CAY10568
HY-122124CAY10583
HY-118988CAY10506
HY-50692-01CAY10734
HY-121537-01CAY10404

Alternative Products

CatalogName
MBS5752436CAY10594

Popular Products